Third Quarter 2019 Results
Bayer AG News Conference Call
Bayer: Encouraging business performance across all divisions – agreements signed to divest Currenta and Animal Health
- Group sales increase by 5.4 percent (Fx & portfolio adj.) to 9.830 billion euros/li>
- EBITDA before special items advances by 7.5 percent to 2.291 billion euros
- Crop Science reports higher sales and substantial earnings growth
- Pharmaceuticals increases sales – earnings decline due to one-time income in prior year
- Consumer Health posts growth in sales (Fx & portfolio adj.) and earnings
- Net income declines by 63.9 percent to 1.036 billion euros – substantial divestment gain included in prior year
- Core earnings per share up by 6.4 percent to 1.16 euros
- Group outlook confirmed and aligned to continuing operations
more
Links
Speaker
Werner Baumann
Recording (dubbed into English):
Q&A Session
Recording (dubbed into English):
Follow us: